3 unknown, 2 recruiting, 1 completed, 1 suspended. 6 Phase 1, 2 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Unknown 2, Completed 1, Recruiting 1, Suspended 1, Terminated 1 |
| Phase 2 | 2 | Recruiting 1, Suspended 1 |
| Early Phase 1 | 1 | Unknown 1 |
Follow HRYZ Biotech Co.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma MASCT-I, Doxorubicin, Ifosfamide - Leiomyosarcoma, Liposarcoma | Phase 2 | Recruiting | HRYZ Biotech Co. | 148 | 2024-02-21 | 2025-07-24 |
| HRYZ-T101 Injection for HPV18 Positive Solid Tumor HRYZ-T101 Injection, Fludarabine + Cyclophosphamide - Cervical Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | HRYZ Biotech Co. | 32 | 2023-11-01 | 2024-02-02 |
| HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor Fludarabine + Cyclophosphamide, HRYZ-T101 TCR-T Cell - Cervical Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 | Unknown | HRYZ Biotech Co. | 17 | 2023-03-21 | 2024-02-02 |
| MASCT-I in Patients With Metastatic or Recurrent Solid Tumors Who Failed Standard Therapy. MASCT-I injection - Solid Tumors | Phase 1 | Completed | HRYZ Biotech Co. | 22 | 2020-04-21 | 2023-05-30 |
| MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma MASCT-I, Camrelizumab,Apatinib - Sarcoma | Early Phase 1 | Unknown | HRYZ Biotech Co. | 60 | 2019-11-22 | 2023-10-23 |
| A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor MASCT-I, PD1 antibody - Advanced Gastric Cancer | Phase 1 | Unknown | HRYZ Biotech Co. | 28 | 2018-04-19 | 2019-08-29 |
| A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors MASCT-I, Ifosfamide, PD1 antibody - Advanced Solid Tumors | Phase 1 | Terminated | HRYZ Biotech Co. | 105 | 2017-02-22 | 2025-07-24 |
| Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA). MASCT:Multiple Antigens Specific Cellular Therapy, The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Suspended | HRYZ Biotech Co. | 100 | 2013-07-01 | 2017-10-18 |
Anus Neoplasms (2) · Penile Neoplasms (2) · Sarcoma (2) · Squamous Cell Carcinoma of Head and Neck (2) · Uterine Cervical Neoplasms (2) · Vaginal Neoplasms (2) · Vulvar Neoplasms (2) · Carcinoma, Hepatocellular (1) · Desmoplastic Small Round Cell Tumor (1) · Fibrosarcoma (1) · Hemangiosarcoma (1) · Histiocytoma, Malignant Fibrous (1) · Leiomyosarcoma (1) · Liposarcoma (1) · Neurofibrosarcoma (1)
Cyclophosphamide (2) · Doxorubicin (2) · Ifosfamide (2) · camrelizumab (2) · fludarabine (2) · spartalizumab (2) · Carboplatin (1) · Cisplatin (1) · Gemcitabine (1) · Injections (1) · apatinib (1)
China (8)
Jian Zhang, Doctor (2) · Ruihua Xu, Doctor (2) · Jiafu JI, Doctor (1) · Xiaohua Wu, Doctor (1) · Xing Zhang (1) · Zhang Xing (1)